Russian Thistle Allergy Shots: The Tumbleweed Allergen With the Strongest SCIT Evidence in Its Family
Russian thistle (Salsola tragus) allergy shots are backed by the only published RCT for any Amaranthaceae allergen — Tabar et al. 2014 (JACI 134:99-105) demonstrated significant symptom and medication reduction in a Spanish multicenter placebo-controlled trial. Sal k 1 (pectin methylesterase) is the species-specific major allergen with 67-85% sensitization; Russian thistle is uniquely associated with severe disabling asthma beyond rhinoconjunctivitis (Carnés 2003 Allergy).
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Russian Thistleis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Russian Thistle Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to russian thistle — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of russian thistle allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of russian thistle immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of russian thistle extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for russian thistle allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing russian thistle extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription russian thistle immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat russian thistle allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Russian Thistle?
The biology, taxonomy, and clinical fingerprint of Russian Thistle — the foundation of how SCIT targets it.
Salsola tragus (Russian thistle / tumbleweed) is the most molecularly characterized Amaranthaceae allergen, with seven WHO/IUIS-listed allergens. Sal k 1 accounts for 92% of the extract's IgE-binding capacity.
- Scientific name
- Salsola tragus (syn. S. kali, S. iberica)
- Family
- Amaranthaceae (includes former Chenopodiaceae per APG IV)Amaranth family (Chenopodioideae subfamily)
- Type
- Annual weed pollen / tumbleweed
- Native to
- Eurasia; introduced and now invasive across western US; the iconic American tumbleweed
- Allergen proteins
- Sal k 1 (pectin methylesterase, major — 67-85% sensitization, 92% of extract IgE-binding capacity)Sal k 4 (profilin — 49% sensitization)Sal k 5 (Ole e 1-like — 30-40% sensitization)Sal k 2, 3, 6, 7 (additional WHO/IUIS-listed allergens)
- Particle size
- 20-30 μm
- Avoidance difficulty
- Nearly impossible
How Russian Thistle Allergy Presents
Symptoms by body system — useful for distinguishing Russian Thistle sensitivity from overlapping allergies and infections.
Respiratory
- Seasonal rhinoconjunctivitis peaking August-October across the western and arid US
- Severe disabling asthma — a distinctive feature of Russian thistle sensitization not typical of most other Amaranthaceae allergens (Carnés 2003 Allergy)
- Sneezing, profuse nasal discharge, and nasal congestion during tumbleweed pollen peak
- Nocturnal cough and chest tightness in asthmatic patients during August-September
- Post-nasal drip and chronic sinusitis overlapping with fall weed season
Ocular
- Intense allergic conjunctivitis on high-count August-September days
- Watery, itchy, red eyes worsened by outdoor exposure in arid wind
- Periorbital swelling during peak tumbleweed rolling season
- Contact lens intolerance from late August through September
Dermal
- Contact dermatitis or urticaria from handling fresh Russian thistle plants
- Pruritus of exposed skin during outdoor activity in areas with dense tumbleweed stands
- Eczema exacerbation in atopic patients during peak pollen season
Systemic
- Significant fatigue and reduced quality of life during prolonged severe rhinitis and asthma
- Sleep disruption from nocturnal asthma symptoms and nasal congestion
- Sal k 4 profilin cross-reactivity may produce OAS-type reactions with some raw foods
- Exercise limitation and reduced outdoor activity tolerance in sensitized athletes
Russian thistle is the one Amaranthaceae allergen where I counsel patients on early immunotherapy consideration — not just for rhinitis but because of the asthma association documented by Carnés et al. in 2003. The Tabar 2014 RCT gives us actual controlled evidence, which is unusual for this plant family. For western US patients with Salsola-driven asthma, a 3-5 year SCIT course can genuinely change the trajectory of their respiratory disease.
When & Where Russian Thistle Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: late August through September; dominant in Phoenix, Las Vegas, Albuquerque, El Paso, and throughout the arid western US· ~10-12 weeks of intense exposure; tumbleweed formation in late fall extends some pollen dispersal beyond the main season
US Exposure Map
10 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Moderate
- MT:
- Moderate
- ND:
- Moderate
- MN:
- Low
- WI:
- Low
- MI:
- Low
- NY:
- Low
- MA:
- Low
- OR:
- Moderate
- ID:
- High
- WY:
- High
- SD:
- Moderate
- IA:
- Low
- IL:
- Low
- IN:
- Low
- OH:
- Low
- PA:
- Low
- NJ:
- Low
- CT:
- Low
- RI:
- Low
- CA:
- High
- NV:
- High
- UT:
- High
- CO:
- High
- NE:
- Moderate
- MO:
- Low
- KY:
- Low
- WV:
- Low
- VA:
- Low
- MD:
- Low
- DE:
- Low
- AZ:
- High
- NM:
- High
- KS:
- Moderate
- AR:
- Low
- TN:
- Low
- NC:
- Low
- SC:
- Low
- OK:
- High
- LA:
- Low
- MS:
- Low
- AL:
- Low
- GA:
- Low
- TX:
- High
- FL:
- Low
- AK:
- Low
- HI:
- Low
What Russian Thistle Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Sal k 1 (pectin methylesterase) is a species-specific marker for Russian thistle — no structural homolog exists in Chenopodium or Amaranthus (Barderas 2002); however, Sal k 4 (profilin) cross-reacts broadly within Amaranthaceae and with pan-allergens across other pollen families, and Sal k 5 (Ole e 1-like) shows limited cross-reactivity with Che a 1 from lamb's quarter (Weber 2007 JACI).
Other Plains tumbleweed; Sal k 4 profilin cross-reacts with Koc s 2; often co-sensitized; similar arid-soil ecology
Sister Chenopodioideae; profilin cross-reactivity; Che a 1 and Sal k 5 show limited Ole e 1-family overlap
Intra-family Atriplex; extract-level cross-reactivity; similar alkaline-soil co-distribution
Is SCIT Right for Your Russian Thistle Allergy?
Answer 5 questions to see whether Russian thistle allergy shots are the right choice for your western US fall allergy pattern.
How severe are your Russian thistle / late-summer fall symptoms (August-October)?
The Russian Thistle SCIT Protocol
Russian thistle SCIT uses non-standardized Salsola tragus extract (no FDA AU/mL standardization) and is typically compounded with kochia, lamb's quarter, and pigweed mix in a fall-weed vial for western US polysensitized patients.
Incremental dose escalation from dilute starting concentration with mandatory 30-minute post-injection observation at every visit. For patients with Salsola-driven asthma, the allergist will assess respiratory status before each injection — asthma should be well-controlled (FEV1 at or near personal best) before proceeding. Build-up should ideally be completed at least 12 weeks before the August tumbleweed pollen peak. Epinephrine auto-injector is required throughout treatment.
Maintenance injections sustain the immunological tolerance established during build-up. Russian thistle extract is commonly compounded with kochia, lamb's quarter, and pigweed mix for western US polysensitized patients — a single fall-weed vial can cover the major Amaranthaceae allergens efficiently. Most patients notice progressive improvement in both rhinitis and asthma severity through successive tumbleweed seasons.
After 3-5 years of maintenance, many patients retain clinically meaningful post-treatment benefit. For patients with severe Salsola-driven asthma, your allergist may recommend extended maintenance given the severity of the underlying disease and the strong evidence supporting continued treatment.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Russian Thistle SCIT
Russian thistle SCIT has the strongest evidence base in the Amaranthaceae family — the only published DBPC-RCT for any Amaranthaceae allergen (Tabar 2014 JACI) — making it the evidence anchor for extrapolation to other family members.
- Symptom score reduction — Salsola SCIT vs placebo42%Tabar AI et al. 2014, JACI 134:99-105, N=48 (Spanish multicenter DBPC-RCT of Salsola kali SCIT)
- Skin sensitization reduction after SCIT55%Tabar AI et al. 2014, JACI 134:99-105 (reduction in skin-prick test reactivity to Salsola extract)
- Basophil activation reduction after SCIT60%Tabar AI et al. 2014, JACI 134:99-105 (flow cytometry basophil activation test outcomes)
- Weed-pollen SCIT medication score reduction50%Cox L et al. 2011, JACI 127:S1-55 (AAAAI Practice Parameter — supporting general weed SCIT data)
The Tabar 2014 JACI multicenter RCT is the definitive SCIT evidence for Russian thistle — the only controlled trial in the entire Amaranthaceae family. It demonstrated significant reduction in symptom scores, skin prick test reactivity, and basophil activation in Salsola-sensitized rhinitis-asthma patients compared to placebo. This evidence, combined with the seven WHO/IUIS-listed allergens making Salsola the best-characterized family member, supports Russian thistle SCIT as the evidence anchor for western US fall-weed immunotherapy.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Russian Thistle SCIT Side Effects
Russian thistle SCIT carries the standard inhalant SCIT side-effect profile, with the additional caution that Salsola-sensitized patients with asthma require careful respiratory status assessment before each injection.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site wheal and flare Standard IgE-mediated local reaction; resolves within 30-60 minutes | Rate 30-50% | Mild |
Injection-site itching | Rate 25-40% | Mild |
Large local reaction (>5 cm) Dose held or reduced at next visit | Rate 5-10% | Moderate |
Delayed local swelling | Rate 2-5% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis or conjunctivitis flare | Rate 1-3% | Mild |
Urticaria | Rate 0.5-1% | Moderate |
Asthma exacerbation Higher risk in Salsola-driven asthma patients; asthma must be well-controlled before each injection; pre-injection spirometry recommended for moderate-severe asthmatics | Rate 0.1-0.5% | Moderate |
Anaphylaxis Managed with epinephrine; the reason a prescribed auto-injector is confirmed on-hand before the first dose and the first injection from each new vial or concentration is supervised live in the Virtual Shot Room by trained Curex clinical staff | Rate <0.1% per injection | Severe |
The asthma association with Russian thistle sensitization makes respiratory status assessment before each injection especially important. With Curex at-home SCIT the serum is sterile-compounded to USP <797>, a prescribed epinephrine auto-injector is confirmed on-hand before your first dose, and the first injection from each new vial or concentration is supervised live in the Virtual Shot Room by trained Curex clinical staff; patients with poorly controlled asthma should not begin injections until their baseline FEV1 is optimized.
SCIT vs Alternatives for Russian Thistle
Russian thistle-sensitized patients have four main options; for those with Salsola-driven asthma, SCIT has the strongest evidence base and the only controlled trial data in this allergen family.
| Criterion | At-home SCIT (Curex)Best | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | High — Tabar 2014 JACI RCT | Moderate — European data extrapolated | Minimal — tumbleweeds ubiquitous | Good symptom control; asthma needs controller |
| 5-yr cost | $3,500-$15,000 | $1,500-$5,000 | Low | $500-$3,000/yr |
| Duration | 3-5 years | 3-5 years | Ongoing | Ongoing daily |
| Convenience | Weekly then monthly at home | Daily home dosing | Nearly impossible West/Plains | Daily pills/sprays/inhalers |
| Safety | Virtual Shot Room–supervised first dose + asthma check | Lower systemic risk | Safe | Safe long-term |
| Lasting effect | Yes — post-treatment | Emerging evidence | No | No — symptoms return off meds |
At-home SCIT (Curex)Best
SLIT
Avoidance
Medications
For western US patients with Salsola-driven rhinitis and asthma, SCIT offers the only disease-modifying approach with controlled trial support — and the only allergen family here with controlled trial data. Curex delivers that SCIT at home with pricing confirmed in a current program quote: sterile-compounded serum, a prescribed epinephrine auto-injector confirmed on-hand, and the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff, so western patients who cannot commit to weekly clinic visits still get true immunological disease modification rather than ongoing medication dependence.
What Russian Thistle SCIT Actually Costs
Russian thistle SCIT is typically covered under standard allergy benefit codes by major US insurers (CPT 95115/95117/95165) when prescribed by a board-certified allergist; for patients with documented Salsola-driven asthma, the Tabar 2014 RCT provides strong medical necessity documentation that can support prior authorization. Actual out-of-pocket cost depends on your plan's deductible and co-insurance. Curex at-home IgE testing identifies specific russian thistle sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your russian thistle allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Russian Thistle SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Yes — Salsola tragus (Russian thistle) is the most iconic tumbleweed of the American West, the familiar dry spherical plant seen blowing across desert roads and piling against fences in late fall. Native to Eurasia, it was accidentally introduced to the US in the 1870s with flaxseed shipments and has spread across the western two-thirds of the country. When it breaks off at the base and tumbles, it disperses both seeds and any remaining pollen. During the growing season (August-September), rooted plants produce abundant wind-dispersed pollen that reaches high counts in Phoenix, Las Vegas, Albuquerque, and other desert cities. If your fall symptoms peak during 'tumbleweed season,' Russian thistle sensitization should be on your allergist's differential.
Yes — this is a documented clinical observation. Carnés et al. (2003 Allergy 58:1190-1196) specifically noted the association between Salsola sensitization and severe, sometimes disabling, asthma beyond the rhinoconjunctivitis typical of most other Amaranthaceae allergens. The mechanism is not fully established but may relate to the enzymatic activity of Sal k 1 (pectin methylesterase), which could have pro-inflammatory effects on airway epithelium. A 2024 study confirmed profilin Sal k 7 as the second most important Salsola allergen, also associated with asthma. If you live in the western US and experience severe asthma attacks specifically in August-September, Russian thistle sensitization is an important diagnostic consideration — even if ragweed is not a major contributor in your region.
Sal k 1 (pectin methylesterase, ~38 kDa) is the major allergen of Salsola tragus — a plant cell-wall enzyme that accounts for 67-85% of sensitization in Salsola-allergic patients and approximately 92% of the whole-extract's IgE-binding capacity (Carnés 2003 Allergy). Critically, Sal k 1 is species-specific: no structural homolog of Sal k 1 exists in Chenopodium album (lamb's quarter) despite both being in the Amaranthaceae family. This means a positive ImmunoCAP w11 (Salsola extract) test is essentially a Sal k 1 test, and that Sal k 1 sensitization cannot be predicted or fully explained by cross-reactivity with other Amaranthaceae members. Russian thistle has seven total WHO/IUIS-listed allergens (Sal k 1-7), making it the most molecularly characterized genus in the family.
The Tabar et al. 2014 study (J Allergy Clin Immunol 134:99-105) is a Spanish multicenter double-blind placebo-controlled randomized trial that assessed the efficacy of Salsola kali subcutaneous immunotherapy. It enrolled 48 patients with Salsola-driven allergic rhinitis and/or asthma and compared active SCIT to placebo over a treatment period. The active treatment group showed statistically significant reductions in combined symptom-medication scores, skin prick test reactivity to Salsola extract, and basophil activation compared to placebo. This trial is the only published DBPC-RCT for any Amaranthaceae allergen and provides the evidentiary foundation that allergists use when counseling patients about Russian thistle — and by family-level extrapolation, other Amaranthaceae — immunotherapy. Its Spanish setting reflects the high prevalence of Salsola sensitization in Mediterranean and arid regions worldwide.
Partially. Sal k 4 (Russian thistle profilin) cross-reacts with Koc s 2 (kochia profilin) and Che a 2 (lamb's quarter profilin) at the pan-allergen level. However, the species-specific major allergens — Sal k 1 (Russian thistle's pectin methylesterase) and Che a 1 (lamb's quarter's Ole e 1-like protein) — do not meaningfully cross-react. For patients sensitized to multiple Amaranthaceae members, most western US allergists compound a combined fall-weed vial containing Russian thistle, lamb's quarter, and kochia extracts together. This three-species vial covers the profilin pan-allergens shared across all three genera and the species-specific major allergens of each, providing comprehensive Amaranthaceae family coverage without requiring three separate injection series.
Yes, typically. Russian thistle SCIT (ImmunoCAP w11, CPT codes 95115/95117/95165) is covered under standard allergy benefits by most major US insurers when prescribed by a board-certified allergist. Prior authorization is routinely required. For patients with documented Salsola-driven asthma, the Tabar 2014 JACI RCT provides robust medical necessity documentation that typically supports prior authorization approval — this is an advantage over allergens without controlled trial evidence. Actual out-of-pocket cost varies by plan deductible, co-insurance, and whether your allergist is in-network. Requesting a benefits verification before your first injection is strongly recommended.
Evidence suggests yes. Allergen immunotherapy, including SCIT for weed pollens, has been shown to prevent the progression of allergic rhinitis to asthma in sensitized patients — a phenomenon documented across multiple allergen classes. For Russian thistle specifically, the Tabar 2014 trial enrolled patients who already had rhinitis and asthma; whether earlier treatment prevents asthma onset has not been studied in a controlled trial for Salsola. However, the biological mechanism of SCIT (shifting immune response from IgE-dominant Th2 toward tolerogenic Th1/Treg patterns) is disease-modifying, not merely symptomatic — meaning successfully completed immunotherapy may reduce future sensitization spread and asthma risk. Your allergist can discuss the evidence for early versus delayed immunotherapy in your specific clinical context.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.